Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
EGLT's Cash to Debt is ranked higher than
98% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. EGLT: No Debt )
EGLT' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: No Debt

Equity to Asset 0.73
EGLT's Equity to Asset is ranked higher than
83% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.73 )
EGLT' s 10-Year Equity to Asset Range
Min: -3.39   Max: 0.73
Current: 0.73

-3.39
0.73
Z-Score: 7.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1936.34
EGLT's Operating margin (%) is ranked higher than
55% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. EGLT: -1936.34 )
EGLT' s 10-Year Operating margin (%) Range
Min: -1934.17   Max: -440.97
Current: -1936.34

-1934.17
-440.97
Net-margin (%) -2253.28
EGLT's Net-margin (%) is ranked higher than
54% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. EGLT: -2253.28 )
EGLT' s 10-Year Net-margin (%) Range
Min: -2250.73   Max: -449.46
Current: -2253.28

-2250.73
-449.46
ROE (%) -107.07
EGLT's ROE (%) is ranked higher than
56% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. EGLT: -107.07 )
EGLT' s 10-Year ROE (%) Range
Min: -444.79   Max: -444.79
Current: -107.07

ROA (%) -71.29
EGLT's ROA (%) is ranked higher than
57% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. EGLT: -71.29 )
EGLT' s 10-Year ROA (%) Range
Min: -155.7   Max: -106.79
Current: -71.29

-155.7
-106.79
ROC (Joel Greenblatt) (%) -1327.06
EGLT's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. EGLT: -1327.06 )
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1137.7   Max: -687.52
Current: -1327.06

-1137.7
-687.52
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.60
EGLT's P/B is ranked higher than
67% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. EGLT: 5.60 )
EGLT' s 10-Year P/B Range
Min: 1.41   Max: 6.22
Current: 5.6

1.41
6.22
P/S 104.30
EGLT's P/S is ranked higher than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. EGLT: 104.30 )
EGLT' s 10-Year P/S Range
Min: 37.92   Max: 603
Current: 104.3

37.92
603
EV-to-EBIT -5.76
EGLT's EV-to-EBIT is ranked higher than
72% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EGLT: -5.76 )
EGLT' s 10-Year EV-to-EBIT Range
Min: -6.7   Max: -0.3
Current: -5.76

-6.7
-0.3
Current Ratio 7.42
EGLT's Current Ratio is ranked higher than
91% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. EGLT: 7.42 )
EGLT' s 10-Year Current Ratio Range
Min: 0.17   Max: 7.42
Current: 7.42

0.17
7.42
Quick Ratio 7.42
EGLT's Quick Ratio is ranked higher than
91% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. EGLT: 7.42 )
EGLT' s 10-Year Quick Ratio Range
Min: 0.17   Max: 7.42
Current: 7.42

0.17
7.42
Days Sales Outstanding 321.61
EGLT's Days Sales Outstanding is ranked higher than
72% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. EGLT: 321.61 )
EGLT' s 10-Year Days Sales Outstanding Range
Min: 56.56   Max: 321.28
Current: 321.61

56.56
321.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
EGLT's Price/Net Cash is ranked higher than
86% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. EGLT: 6.50 )
EGLT' s 10-Year Price/Net Cash Range
Min: 2.7   Max: 2.7
Current: 6.5

Price/Net Current Asset Value 6.30
EGLT's Price/Net Current Asset Value is ranked higher than
85% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. EGLT: 6.30 )
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.53   Max: 2.53
Current: 6.3

Price/Tangible Book 5.40
EGLT's Price/Tangible Book is ranked higher than
77% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. EGLT: 5.40 )
EGLT' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 3.71
Current: 5.4

1.9
3.71
Price/Median PS Value 0.80
EGLT's Price/Median PS Value is ranked higher than
86% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. EGLT: 0.80 )
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 0.35
Current: 0.8

Earnings Yield (Greenblatt) -20.00
EGLT's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. EGLT: -20.00 )
EGLT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -38   Max: 0
Current: -20

-38
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage decreases Mar 27 2015
EGALET CORP Files SEC form 8-K/A, Financial Statements and Exhibits Mar 25 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
Egalet to hire up to 60 sales reps for launch of two pain medicines Mar 25 2015
Egalet Provides Commercial Update on SPRIX® and OXAYDO™ Mar 25 2015
6:01 am Egalet announces commercial update on SPRIX and OXAYDO Mar 25 2015
Egalet Provides Commercial Update on SPRIX® and OXAYDO™ Mar 25 2015
Rigontec GmbH Raises €4.8m in a Second Closing of its Series A Financing Mar 24 2015
EGALET CORP Files SEC form 8-K, Other Events Mar 23 2015
EGALET CORP Financials Mar 21 2015
Surging Earnings Estimates Signal Good News for Egalet Corp (EGLT) - Tale of the Tape Mar 19 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 18 2015
Egalet Earns $10 Million Milestone Payment Triggered by Advancement of Shionogi's Abuse-Deterrent,... Mar 17 2015
Egalet Earns $10 Million Milestone Payment Triggered by Advancement of Shionogi's Abuse-Deterrent,... Mar 17 2015
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 16 2015
Egalet (EGLT) Shares March Higher, Can It Continue? - Tale of the Tape Mar 16 2015
Egalet Accelerates Development of Abuse-Deterrent Morphine Egalet-001 and Plans to File New Drug... Mar 16 2015
Egalet Reports Full Year 2014 Financial Results Mar 16 2015
Egalet Reports Full Year 2014 Financial Results Mar 16 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK